Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice

Guidelines on atrial fibrillation (AF) recommend the CHA2DS2-VASc rule for anticoagulant decision-making, but underuse exists. We studied the impact of an automated decision support on stroke prevention in patients with AF in a cluster randomised trial in general practice. Intervention practices wer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2018-12, Vol.273, p.123-129
Hauptverfasser: van Doorn, S., Rutten, F.H., O'Flynn, C.M., Oudega, R., Hoes, A.W., Moons, K.G.M., Geersing, G.J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 129
container_issue
container_start_page 123
container_title International journal of cardiology
container_volume 273
creator van Doorn, S.
Rutten, F.H.
O'Flynn, C.M.
Oudega, R.
Hoes, A.W.
Moons, K.G.M.
Geersing, G.J.
description Guidelines on atrial fibrillation (AF) recommend the CHA2DS2-VASc rule for anticoagulant decision-making, but underuse exists. We studied the impact of an automated decision support on stroke prevention in patients with AF in a cluster randomised trial in general practice. Intervention practices were provided with a CHA2DS2-VASc based anticoagulant treatment recommendation. Reference practices provided care as usual. The primary outcome was incidence of ischaemic stroke, transient ischaemic attack (TIA) and/or thromboembolism (TE). Secondary outcomes were bleeding and the proportion of patients on guideline recommended anticoagulant treatment. In total, 1129 AF patients were included in the 19 intervention practices and 1226 AF patients in the 19 reference practices. The median age was 77 (interquartile range (IQR) 68–75) years, the median CHA2DS2-VASc score was 3.0 (IQR 2.0–5.0). Underuse of anticoagulants in patients with CHA2DS2-VASc score ≥ 2 was 6.6%. After a median follow-up of 2.7 years (IQR 2.3–3.0), the incidence rate per 100 person-years of ischaemic stroke/TIA/TE was 1.96 in the intervention group and 1.42 in the reference group (hazard ratio (HR) 1.3, 95% C.I. 0.8–2.1). No difference was observed in the rate of bleeding (0.79 versus 0.82), or in the underuse (7.2% versus 8.2%) or overuse (8.0% versus 7.9%) of anticoagulation. In this study in patients with AF in general practice, underuse of anticoagulants was relatively low. Providing practitioners with CHA2DS2-VASc based decision support did not result in a reduction in stroke incidence, affect bleeding risk or anticoagulant over- or underuse. •Underuse of anticoagulants is common in patients with atrial fibrillation (AF).•We evaluated a based decision support system in general practice.•Anticoagulant underuse in those with CHA2DS2-VASc ≥2 was low at only 6.6%.•No difference was found in the rate of stroke, bleeding or use of anticoagulation.
doi_str_mv 10.1016/j.ijcard.2018.08.096
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2109332219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527318336854</els_id><sourcerecordid>2109332219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c269t-d05f30633b87b4c60e3e01c2d33283b4ab6c58bc08324c8edd7027635b435f543</originalsourceid><addsrcrecordid>eNp9UctKBDEQDKLguvoHHnL0Mmte8_IgLOsTBA8-riGT9EjWcTJ2ZgX_wk82w3gWGtKkqyrVKUJOOVtxxovz7cpvrUG3EoxXK5aqLvbIglelyniZq32ySLAyy0UpD8lRjFvGmKrrakF-rtsW7Oi_oIcYaWjp5m4trp5E9rp-srQxERx1YH30oadxNwwBRzq1I4Z3oANCoo7T0PfUjOhNR1vfoO86M11f0DW13S6OgBRN78KHnyRnYKK8pYcxtQOaZMPCMTloTRfh5O9ckpeb6-fNXfbweHu_WT9kVhT1mDmWt5IVUjZV2ShbMJDAuBVOSlHJRpmmsHnVWFZJoWwFzpVMlIXMGyXzNldySc5m3QHD5w7iqJMxC8l1D2EXteCsTlqC1wmqZqjFECNCqwf0Hwa_NWd6CkBv9RyAngLQLFVdJNrlTIO0xpcH1NF66C04j-nLtQv-f4FfBTGSKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2109332219</pqid></control><display><type>article</type><title>Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice</title><source>Elsevier ScienceDirect Journals Complete</source><creator>van Doorn, S. ; Rutten, F.H. ; O'Flynn, C.M. ; Oudega, R. ; Hoes, A.W. ; Moons, K.G.M. ; Geersing, G.J.</creator><creatorcontrib>van Doorn, S. ; Rutten, F.H. ; O'Flynn, C.M. ; Oudega, R. ; Hoes, A.W. ; Moons, K.G.M. ; Geersing, G.J.</creatorcontrib><description>Guidelines on atrial fibrillation (AF) recommend the CHA2DS2-VASc rule for anticoagulant decision-making, but underuse exists. We studied the impact of an automated decision support on stroke prevention in patients with AF in a cluster randomised trial in general practice. Intervention practices were provided with a CHA2DS2-VASc based anticoagulant treatment recommendation. Reference practices provided care as usual. The primary outcome was incidence of ischaemic stroke, transient ischaemic attack (TIA) and/or thromboembolism (TE). Secondary outcomes were bleeding and the proportion of patients on guideline recommended anticoagulant treatment. In total, 1129 AF patients were included in the 19 intervention practices and 1226 AF patients in the 19 reference practices. The median age was 77 (interquartile range (IQR) 68–75) years, the median CHA2DS2-VASc score was 3.0 (IQR 2.0–5.0). Underuse of anticoagulants in patients with CHA2DS2-VASc score ≥ 2 was 6.6%. After a median follow-up of 2.7 years (IQR 2.3–3.0), the incidence rate per 100 person-years of ischaemic stroke/TIA/TE was 1.96 in the intervention group and 1.42 in the reference group (hazard ratio (HR) 1.3, 95% C.I. 0.8–2.1). No difference was observed in the rate of bleeding (0.79 versus 0.82), or in the underuse (7.2% versus 8.2%) or overuse (8.0% versus 7.9%) of anticoagulation. In this study in patients with AF in general practice, underuse of anticoagulants was relatively low. Providing practitioners with CHA2DS2-VASc based decision support did not result in a reduction in stroke incidence, affect bleeding risk or anticoagulant over- or underuse. •Underuse of anticoagulants is common in patients with atrial fibrillation (AF).•We evaluated a based decision support system in general practice.•Anticoagulant underuse in those with CHA2DS2-VASc ≥2 was low at only 6.6%.•No difference was found in the rate of stroke, bleeding or use of anticoagulation.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2018.08.096</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Anticoagulants ; Atrial fibrillation ; CHA2DS2-VASc ; Decision support system</subject><ispartof>International journal of cardiology, 2018-12, Vol.273, p.123-129</ispartof><rights>2018 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c269t-d05f30633b87b4c60e3e01c2d33283b4ab6c58bc08324c8edd7027635b435f543</citedby><cites>FETCH-LOGICAL-c269t-d05f30633b87b4c60e3e01c2d33283b4ab6c58bc08324c8edd7027635b435f543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2018.08.096$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>van Doorn, S.</creatorcontrib><creatorcontrib>Rutten, F.H.</creatorcontrib><creatorcontrib>O'Flynn, C.M.</creatorcontrib><creatorcontrib>Oudega, R.</creatorcontrib><creatorcontrib>Hoes, A.W.</creatorcontrib><creatorcontrib>Moons, K.G.M.</creatorcontrib><creatorcontrib>Geersing, G.J.</creatorcontrib><title>Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice</title><title>International journal of cardiology</title><description>Guidelines on atrial fibrillation (AF) recommend the CHA2DS2-VASc rule for anticoagulant decision-making, but underuse exists. We studied the impact of an automated decision support on stroke prevention in patients with AF in a cluster randomised trial in general practice. Intervention practices were provided with a CHA2DS2-VASc based anticoagulant treatment recommendation. Reference practices provided care as usual. The primary outcome was incidence of ischaemic stroke, transient ischaemic attack (TIA) and/or thromboembolism (TE). Secondary outcomes were bleeding and the proportion of patients on guideline recommended anticoagulant treatment. In total, 1129 AF patients were included in the 19 intervention practices and 1226 AF patients in the 19 reference practices. The median age was 77 (interquartile range (IQR) 68–75) years, the median CHA2DS2-VASc score was 3.0 (IQR 2.0–5.0). Underuse of anticoagulants in patients with CHA2DS2-VASc score ≥ 2 was 6.6%. After a median follow-up of 2.7 years (IQR 2.3–3.0), the incidence rate per 100 person-years of ischaemic stroke/TIA/TE was 1.96 in the intervention group and 1.42 in the reference group (hazard ratio (HR) 1.3, 95% C.I. 0.8–2.1). No difference was observed in the rate of bleeding (0.79 versus 0.82), or in the underuse (7.2% versus 8.2%) or overuse (8.0% versus 7.9%) of anticoagulation. In this study in patients with AF in general practice, underuse of anticoagulants was relatively low. Providing practitioners with CHA2DS2-VASc based decision support did not result in a reduction in stroke incidence, affect bleeding risk or anticoagulant over- or underuse. •Underuse of anticoagulants is common in patients with atrial fibrillation (AF).•We evaluated a based decision support system in general practice.•Anticoagulant underuse in those with CHA2DS2-VASc ≥2 was low at only 6.6%.•No difference was found in the rate of stroke, bleeding or use of anticoagulation.</description><subject>Anticoagulants</subject><subject>Atrial fibrillation</subject><subject>CHA2DS2-VASc</subject><subject>Decision support system</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UctKBDEQDKLguvoHHnL0Mmte8_IgLOsTBA8-riGT9EjWcTJ2ZgX_wk82w3gWGtKkqyrVKUJOOVtxxovz7cpvrUG3EoxXK5aqLvbIglelyniZq32ySLAyy0UpD8lRjFvGmKrrakF-rtsW7Oi_oIcYaWjp5m4trp5E9rp-srQxERx1YH30oadxNwwBRzq1I4Z3oANCoo7T0PfUjOhNR1vfoO86M11f0DW13S6OgBRN78KHnyRnYKK8pYcxtQOaZMPCMTloTRfh5O9ckpeb6-fNXfbweHu_WT9kVhT1mDmWt5IVUjZV2ShbMJDAuBVOSlHJRpmmsHnVWFZJoWwFzpVMlIXMGyXzNldySc5m3QHD5w7iqJMxC8l1D2EXteCsTlqC1wmqZqjFECNCqwf0Hwa_NWd6CkBv9RyAngLQLFVdJNrlTIO0xpcH1NF66C04j-nLtQv-f4FfBTGSKg</recordid><startdate>20181215</startdate><enddate>20181215</enddate><creator>van Doorn, S.</creator><creator>Rutten, F.H.</creator><creator>O'Flynn, C.M.</creator><creator>Oudega, R.</creator><creator>Hoes, A.W.</creator><creator>Moons, K.G.M.</creator><creator>Geersing, G.J.</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181215</creationdate><title>Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice</title><author>van Doorn, S. ; Rutten, F.H. ; O'Flynn, C.M. ; Oudega, R. ; Hoes, A.W. ; Moons, K.G.M. ; Geersing, G.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c269t-d05f30633b87b4c60e3e01c2d33283b4ab6c58bc08324c8edd7027635b435f543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anticoagulants</topic><topic>Atrial fibrillation</topic><topic>CHA2DS2-VASc</topic><topic>Decision support system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Doorn, S.</creatorcontrib><creatorcontrib>Rutten, F.H.</creatorcontrib><creatorcontrib>O'Flynn, C.M.</creatorcontrib><creatorcontrib>Oudega, R.</creatorcontrib><creatorcontrib>Hoes, A.W.</creatorcontrib><creatorcontrib>Moons, K.G.M.</creatorcontrib><creatorcontrib>Geersing, G.J.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Doorn, S.</au><au>Rutten, F.H.</au><au>O'Flynn, C.M.</au><au>Oudega, R.</au><au>Hoes, A.W.</au><au>Moons, K.G.M.</au><au>Geersing, G.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice</atitle><jtitle>International journal of cardiology</jtitle><date>2018-12-15</date><risdate>2018</risdate><volume>273</volume><spage>123</spage><epage>129</epage><pages>123-129</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>Guidelines on atrial fibrillation (AF) recommend the CHA2DS2-VASc rule for anticoagulant decision-making, but underuse exists. We studied the impact of an automated decision support on stroke prevention in patients with AF in a cluster randomised trial in general practice. Intervention practices were provided with a CHA2DS2-VASc based anticoagulant treatment recommendation. Reference practices provided care as usual. The primary outcome was incidence of ischaemic stroke, transient ischaemic attack (TIA) and/or thromboembolism (TE). Secondary outcomes were bleeding and the proportion of patients on guideline recommended anticoagulant treatment. In total, 1129 AF patients were included in the 19 intervention practices and 1226 AF patients in the 19 reference practices. The median age was 77 (interquartile range (IQR) 68–75) years, the median CHA2DS2-VASc score was 3.0 (IQR 2.0–5.0). Underuse of anticoagulants in patients with CHA2DS2-VASc score ≥ 2 was 6.6%. After a median follow-up of 2.7 years (IQR 2.3–3.0), the incidence rate per 100 person-years of ischaemic stroke/TIA/TE was 1.96 in the intervention group and 1.42 in the reference group (hazard ratio (HR) 1.3, 95% C.I. 0.8–2.1). No difference was observed in the rate of bleeding (0.79 versus 0.82), or in the underuse (7.2% versus 8.2%) or overuse (8.0% versus 7.9%) of anticoagulation. In this study in patients with AF in general practice, underuse of anticoagulants was relatively low. Providing practitioners with CHA2DS2-VASc based decision support did not result in a reduction in stroke incidence, affect bleeding risk or anticoagulant over- or underuse. •Underuse of anticoagulants is common in patients with atrial fibrillation (AF).•We evaluated a based decision support system in general practice.•Anticoagulant underuse in those with CHA2DS2-VASc ≥2 was low at only 6.6%.•No difference was found in the rate of stroke, bleeding or use of anticoagulation.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ijcard.2018.08.096</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2018-12, Vol.273, p.123-129
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_2109332219
source Elsevier ScienceDirect Journals Complete
subjects Anticoagulants
Atrial fibrillation
CHA2DS2-VASc
Decision support system
title Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A31%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20CHA2DS2-VASc%20based%20decision%20support%20on%20stroke%20prevention%20in%20atrial%20fibrillation:%20A%20cluster%20randomised%20trial%20in%20general%20practice&rft.jtitle=International%20journal%20of%20cardiology&rft.au=van%20Doorn,%20S.&rft.date=2018-12-15&rft.volume=273&rft.spage=123&rft.epage=129&rft.pages=123-129&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2018.08.096&rft_dat=%3Cproquest_cross%3E2109332219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2109332219&rft_id=info:pmid/&rft_els_id=S0167527318336854&rfr_iscdi=true